Treatment strategies for hepatitis C: Intervention prior to liver transplant, pre-emptively or after established disease

Clinics in Liver Disease

Volumn 7, Issue 3, 2003, Pages 631-650

  Berenguer, Marina ^a   Wright, Teresa L ^b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CYCLOSPORIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PEGINTERFERON ALPHA2B; RIBAVIRIN; STEROID; TACROLIMUS; VIRUS RNA;

CONTROLLED STUDY; DISEASE SEVERITY; GRAFT FAILURE; HEMOLYSIS; HEPATITIS C; HISTORY; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; REOPERATION; REVIEW; SURVIVAL; TREATMENT OUTCOME; VIRUS LOAD;

EID: 0042334652     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-3261(03)00059-X     Document Type: Review

References (75)

1. Wright TL, Donegan E, Hsu H, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992;103:317-22.
2. Chazouilleres O, Kim M, Combs C, et al. Quantitation of Hepatitis C Virus RNA in Liver Transplant Recipients. Gastroenterology 1994;106:994-9.
3. Gane E, Portmann B, Naoumov N, et al. Long-Term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334:815-20.
4. Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36: 202-10.
5. Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889-96.
6. Prieto M, Berenguer M, Rayón M, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes. Hepatology 1999;29:250-6.
7. Berenguer M, Rayón M, Prieto M, et al. Are post-transplantation protocol liver biopsies useful in the long-term? Liver 2001;7:790-6.
8. Feray C, Caccamo L, Alexander GJM, et al. European Collaborative Study on factors influencing the outcome after liver transplantation for hepatitis C. Gastroenterology 1999;117:619-25.
9. Testa G, Crippin JS, Netto GJ, et al. Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients. Liver Transpl 2000;6:553-61.
10. Sanchez-Fueyos A, Restrepo J-C, Quintó L, et al. Impact of the recurrence of hepatitis C infection after liver transplantation on the long term viability of the graft. Transplantation 2002;73:56-63.
11. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000;32:673-84.
12. Berenguer M, Prieto M, Rayón JM, et al. Natural history of clinically compensated HCV-related graft cirrhosis following liver transplantation. Hepatology 2000;32:852-8.
13. Fattovitch G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72.
14. Schluger L, Sheiner P, Thung S, et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996;23:971-6.
15. Serfarty L, Aumaître H, Chazouillères O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998;27:1435-40.
16. Heathcote EJ, Shiffmann ML, Cooksley GE, et al. Peginterferon alfa 2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-80.
17. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358:958-65.
18. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa 2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 Sep 26;347(13):975-82.
19. Keeffe EB. Liver Transplantation: Current Status and Novel Approaches to Liver Replacement. Gastroenterology 2001;120:749-62.
20. Adams MB, Mantyh NM. Adult living donor liver transplantation. Current Opinion in Organ Transplantation 2001;6:363-6.
21. Wiesner RH, McDiarmid SV, Kamath PS. MELD and PELD: application or survival models to liver allocation. Liver Transplant 2001;7:567-80.
22. Figueras J, Jaurrieta E, Valls C, et al. Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: a comparative study. Hepatology 1997;25:1485-9.
23. Moya A, Berenguer M, Aguilera V, et al. Hepatocellular carcinoma: can it be considered a controversial indication for liver transplantation in centers with high rates of hepatitis C? Liver Transpl 2002 Nov;8(11):1020-7.
24. Suarez Y, Franca ACV, Llovet JM, Fuster J, Bruix J. The current status of liver transplantation for primary hepatic malignancy. Clinics Liver Disease 2000;4:591-605.
25. Kubo S, Nishighushi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 2002;89:418-22.
26. Feray C, Gigou M, Samuel D, et al. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann Intern Med 1998; 128:810-6.
27. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998;28:823-30.
28. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998;282:103-7.
29. Crippin JS, Sheiner P, Terrault NA, et al. A pilot study of the tolerability and efficacy of antiviral therapy in patients awaiting liver transplantation for hepatitis C. Liver Transplantation 2002;8: 350-5.
30. Everson GT, Trouillot T, Trotter J, et al. Treatment of decompensated cirrhotics with a slow-accelerating dose regimen (LADR) of interferon-alfa-2b plus ribavirin: safety and efficacy. Hepatology 2000;32:308A.
31. Sheiner P, Boros P, Klion FM, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998;28:831-8.
32. Singh N, Gayowski T, Wannstedt C, et al. Interferon-α for prophylaxis of recurrent viral hepatitis C in liver transplant recipients. Transplantation 1998;65:82-6.
33. Mazzaferro V, Tagger A, Schiavo M, et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transpl Proc 2001;33:1355-7.
34. Wright TL, Combs C, Kim M, et al. Interferon alpha therapy for hepatitis C virus infection following liver transplantation. Hepatology 1994;20:773-9.
35. Feray C, Samuel D, Gigou M, et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology 1995;22:1084-9.
36. Gane EJ, Lo SK, Riordan SM, et al. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998;27: 1403-7.
37. Safadi R, Shouval D, Kaspa RT, Ashur Y, Ilan Y. Beneficial effect of ribavirin on hepatitis C-associated cryoglobulinemia after liver transplantation. Liver Transpl Surg 1996;2:263-8.
38. Singh N, Gayowski T, Wannstedt CF, et al. Interferon-alpha therapy for hepatitis C virus recurrence after liver transplantation: long-term response with maintenance therapy. Clin Transplant 1996;10:348-51.
39. Comberg M, Jaeckel E, Manns MP. Treatment of Acute Hepatitis C with Interferon Alfa-2b. N Engl J Med 2002;346:1091-2.
40. Vargas V, Charco R, Castells L, et al. Alpha-interferon for acute hepatitis C in liver transplant patients. Transpl Proc 1995;27:1222-3.
41. Boillot O, Berger F, Rasalofo E, et al. Effects of early interferon alfa therapy for hepatitis C virus infection recurrence after liver transplantation. Transpl Proc 1995;27:2501-2.
42. Bizollon T, Palazzo U, Ducerf C, et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997;26: 500-4.
43. Bizollon T, Ducerf C, Chevallier M, et al. Long-term efficacy of ribavirin plus IFN in the treatment of HCV recurrence after liver transplantation. 11th Congress of the European Society for Organ Transplantation. Oslo, [abstract 20]. June 19-24, 1999.
44. Alberti AB, Belli LS, Airoldi A, et al. Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: a pragmatic study. Liver Transpl 2001;7: 870-6.
45. Gopal DV, Rabkin JM, Berk BS, et al. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin. Liver Transpl 2001;7:181-90.
46. Ahmad J, Dodson SF, Demetris AJ, Fung JJ, Shakil AO. Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin. Liver Transpl 2001;7:863-9.
47. De Vera ME, Smallwood GA, Rosado K, et al. Interferon-alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation. Transplantation 2001;71:678-86.
48. Narayanan M, Poterucha JJ, El-Amin OM, et al. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl 2002; 8:623-9.
49. Saab S, Ly D, Han SB, et al. Is it cost-effective to treat recurrent hepatitis C infection in orthotopic liver transplantation patients? Liver Transpl 2002;8:449-57.
50. Lavezzo B, Franchello A, Smedile A, et al. Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus twelve month course of interferon alfa 2b with ribavirin. J Hepatol 2002;37:247-52.
51. Andreone P, Gramenzi A, Cursaro C, et al. Interferon-alpha plus ribavirin and amantadine in patients with post-transplant hepatitis C: results of a pilot study. Digest Liver Dis 2001;33: 693-8.
52. Brillanti S, Vivarelli M, Abdiueli-Aden A, et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl 2002; In press.
53. Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000;32: 1125-30.
54. Casanovas T, Ramos E, Serrano T, et al. Pilot study with the combination of interferon-alpha and ribavirin for recurrent post-liver transplantation hepatitis C. Causes of treatment failure in two different populations [abstract]. Hepatology 2001;34:477.
55. Doughty AL, Spencer JD, Cossart YE, McCaughan GW. Cholestatic hepatitis post liver transplant is associated with persistently high serum hepatitis C virus RNA levels. Liver Transpl Surg 1998;4:15-21.
56. Ong JP, Younossi ZM, Gramlich T, et al. Interferon-alpha 2B and ribavirin in severe recurrent cholestatic hepatitis C. Transplantation 2001;71:1486-8.
57. Gigou M, Roque-Alfonso AM, Falissard B, et al. Genetic clustering of hepatitis C virus strains and severity of recurrent hepatitis after liver transplantation. J Virol 2001;75:11292-7.
58. Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and Liver Transplantation. J Hepatol 2001;35:666-78.
59. Rosen HR, Hinrichs DJ, Gretch DR, et al. Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation. Gastroenterology 1999;117: 926-32.
60. Rosen HR, Gretch DR, Oehlke M, et al. Timing and severity of initial hepatitis C recurrence as predictors of long-term liver allograft injury. Transplantation 1998;65:1178-82.
61. DiMartino V, Saurini F, Samuel D, et al. Long-term longitudinal study of intrahepatic hepatitis C virus replication after liver transplantation. Hepatology 1997;26:1343-50.
62. Guido M, Thung SN. Distinguishing rejection from recurrent viral hepatitis on liver biopsy. Viral hepatitis 1998;4:127-36.
63. Jain A, Kashyap R, Demetris AJ, et al. A prospective randomized trial of Mycophenolate Mofetil in liver transplant recipients with hepatitis C. Liver Transpl 2002;8:40-6.
64. Nelson DR, Soldevila-Pico C, Reed A, et al. The effect of anti-interleukin-2 receptor therapy on the course of hepatitis C recurrence after liver transplantation. Liver Transpl 2001;7:1064-70.
65. Busuttil RW, Shaked A, Millis JM, et al. One thousand liver transplants. The lessons learned. Ann Surg 1994;219:490-9.
66. Casavilla FA, Rakela J, Kapur S, et al. Clinical outcome of patients infected with hepatitis C virus infection on survival after primary liver transplantation under tacrolimus. Liver Transpl Surg 1998;4:448-54.
67. Zervos XA, Weppler D, Fragulidis GP, et al. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. Transplantation 1998;65:1044-6.
68. Papatheodoridis G, Patch D, Dusheiko G, Burroughs A. The outcome of hepatitis C virus infection after liver transplantation; Is it influenced by the type of immunosuppression? J of Hepatology 1999;30:731-8.
69. Biggins SW, Beldecos A, Rabkin JM, Rosen HR. Retransplantation for hepatic allograft failure: prognostic modeling and ethical considerations. Liver Transpl 2002;8:313-22.
70. Rosen HR, Martin P. Hepatitis C infection in patients undergoing liver retransplantation. Transplantation 1998;66:1612-6.
71. Sheiner PA, Schluger LK, Emre S, et al. Retransplantation for recurrent hepatitis C. Liver Transpl Surg 1997;3:130-6.
72. Rosen H, O'Reilly P, Shackleton C, et al. Graft loss following liver transplantation in patients with chronic hepatitis C. Transplantation 1997;62:1773-6.
73. Facciuto M, Heidt D, Guarrera J, et al. Retransplantation for late liver graft failure: predictors of mortality. Liver Transpl 2000;6:174-9.
74. Rosen HR, Madden JP, Martin P. A model to predict survival following liver retransplantation. Hepatology 1999;29:365-70.
75. Berenguer M, Prieto M, Palau A, et al. Severe recurrent hepatitis C following liver retransplantation for HCV-related graft failure. Liver Transpl 2002;Mar9:228-35.